After previously extending telemedicine flexibilities via temporary rules, the Drug Enforcement Administration (DEA) now seems poised to retreat from its pandemic stance and drastically limit providers’ abilities to prescribe controlled substances via telemedicine.
Sean Sullivan, Sofia Molodanof, and Anthony Fanucci report on when we might see a final rule, the likely new limitations, and how the new rule will impact providers.
Subscribe to Our Health Care Updates >
View More Healthy Bytes > | View Our Digital Health Care Services >